Transform Your Future: Ace the 2025 Certified Diabetes Educator Exam!

DPP-4 inhibitors, also known as dipeptidyl peptidase-4 inhibitors, specifically refer to a class of medications that are recognized for their role in managing type 2 diabetes by increasing the levels of incretin hormones. These hormones help to regulate blood glucose levels by stimulating insulin secretion in response to meals and inhibiting glucagon release.

Medications in the DPP-4 inhibitor class are characterized by their generic names typically ending in "-gliptin." Examples include sitagliptin, saxagliptin, linagliptin, and alogliptin. This naming convention helps healthcare providers and patients to easily identify these medications based on their chemical structure and mechanism of action.

The other options indicate different classes of medications that do not pertain to DPP-4 inhibitors. Medications ending in "-etin" are typically associated with GLP-1 receptor agonists, which have a different mechanism for blood sugar control. Medications ending in "-sulin" are insulin therapies used primarily for type 1 diabetes and sometimes for advanced type 2 diabetes management. Lastly, medications ending in "-togliflozin" refer to SGLT2 inhibitors, which work by preventing glucose reabsorption in the